Filgrastim Market Is Expected to Experience Steep Growth by 2025
Granulocyte colony stimulating factor is referred as stimulating factor 3, which acts to increase production of stem cells and granulocytes. Filgrastim is a granulocyte colony stimulating factor (G-CSF) prepared by recombinant DNA technology and often used in the treatment of low blood neutrophils. It is also frequently used in conditions where lukapheresis with increased white blood cells is observed. Common adverse effects of Filgrastim include joint pain, chest pain, hair loss, and vomiting.
View full press release